Phosphodiesterase 4 (PDE4) is an enzyme known to play a role in inflammatory responses, and it has been pinpointed as an interesting therapeutic target for diseases like atopic dermatitis (AD), but ...

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream ...

WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations ...

Advances in Systemic Therapies for Atopic Dermatitis: Systemic therapies for atopic dermatitis have advanced significantly in recent years, with numerous new agents, including IL-4 and IL-13 pathway ...

Eucrisa is a brand-name form of the generic medication crisaborole. Doctors prescribe it in topical form to help manage mild to moderate eczema. It belongs to a drug class called phosphodiesterase 4 ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

NEW YORK CITY – The substantial and ongoing growth in therapeutic options for atopic dermatitis (AD) means that treatments can be personalized across phenotypes, specific symptoms, and patient goals, ...

Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the importance of individualized regimens that balance efficacy and safety, ...

Topical corticosteroids (TCS); tacrolimus, 0.1%; and topical JAK inhibitors were among the most effective treatments for short-term control of atopic dermatitis (AD) according to a recent network meta ...